Two flops in two weeks for Marinus Pharmaceuticals' ganaxolone
Days after Marinus Pharmaceutical’s ganaxolone failed on an epilepsy study, the same drug failed a Fragile X syndrome trial, further bruising the biotech’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
